^
BIOMARKER:

MYC rearrangement + BCL2 rearrangement

i
Other names: MYC, bHLHe39, c-Myc, MYCC, V-myc avian myelocytomatosis viral oncogene homolog, BCL2, Bcl-2, PPP1R50, B-cell CLL/lymphoma 2
Entrez ID:
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
lisocabtagene maraleucel
Sensitive: A2 - Guideline
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
lenalidomide
Sensitive: B - Late Trials
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
cytarabine + methotrexate
Resistant: C3 – Early Trials
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
rituximab
Resistant: C3 – Early Trials
MYC rearrangement + BCL2 rearrangement
Lymphoma
lisocabtagene maraleucel
Sensitive: C3 – Early Trials
MYC rearrangement + BCL2 rearrangement
NHL
ibrutinib
Sensitive: C3 – Early Trials
MYC rearrangement + BCL2 rearrangement
Follicular Lymphoma
EPOCH-R
Sensitive: C3 – Early Trials
MYC rearrangement + BCL2 rearrangement
Follicular Lymphoma
R-DHAP
Sensitive: C3 – Early Trials
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
lenalidomide + zanubrutinib
Sensitive: C3 – Early Trials
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
loncastuximab tesirine
Sensitive: C3 – Early Trials
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
C-RICE
Sensitive: C3 – Early Trials
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
IACS-010759
Sensitive: D – Preclinical
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
ibrutinib
Resistant: D – Preclinical
MYC rearrangement + BCL2 rearrangement
NHL
ibrutinib + alemtuzumab
Sensitive: D – Preclinical